SWOT Analysis for Spero Therapeutics Inc

Price crossing above SMA20 today, and greater than SMA5
Relative Outperformance versus Industry over 1 Week
Significant (over 30%) distance from 52 week high
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Affordable Stocks - Stocks with Good Trendlyne Valuation Score
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Company with Low Debt
Increasing Revenue every quarter for the past 2 quarters
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
High Volume, High Gain
Top Gainers
RSI indicating price strength
Volume Shockers
High Volume, High Gain
Biggest Price Gainers from Open

Stocks in the PE Sell Zone
Stocks with Quarter Change % less than Industry
PE higher than Industry PE
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Highest fall from 52 Week High
Near 52 Week Low
Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Recent Results: Declining Operating Profit Margin and Net Profits (YoY)
Stocks Underperforming their Industry Price Change in the Quarter